Novo Nordisk to slash prices of weightloss drugs in US / Photo: SCOTT OLSON - GETTY IMAGES NORTH AMERICA/AFP/File
-
Kenya's economy faces climate change risks: World Bank
-
France's largest wildfire in decades 'under control', says minister
-
South Korea baseball league cancels two games over heatwave
-
Warsaw and Kyiv exhume Volyn victims at centre of diplomatic quarrel
-
India PM Modi says he forgives protesters who abused him
-
California lifeguards wiped out from extreme weather
-
US plans steep water cuts for southwest amid Colorado River crisis
-
Amazon surges as US stocks shrug off bond yield worries
-
Oil giants report blowout profits on war, warn high gas prices could persist
-
Hungary to shut nuclear plant as heatwave hits central Europe
-
Google launches new satellite image AI tool, alarming researchers
-
Tech-fuelled rally fizzles as oil prices rise
-
US Fed dissenters call for rate hikes over sustained inflation
-
Alarm over climate-linked low level of German waterways
-
New York sues online prediction markets giant Kalshi
-
Commerzbank agrees to talks with UniCredit after two-year standoff
-
Profits surge at US oil giant amid Iran war supply shock
-
Fornaro Legal Releases Guidance to Help Businesses Maintain Clear Ownership Records During Growth
-
Stock markets rally on tech rebound
-
Japan probe made closest-ever asteroid flyby: space agency
-
France, Spain assess scorched terrain as new wildfires threaten other regions
-
British oil giant BP aims to sell North Sea business
-
Chipmaker Kioxia reports AI-driven 45-fold surge in quarterly net profit
-
China factory activity slides as leaders seek spending boost
-
Far right and far left battle for power in polarised Berlin
-
Tech rebound fuels record-breaking rally in South Korean stocks
-
The last trio: S.Africa's zoo elephants await their fate
-
Cables and cooling bring AI windfall to Indian suppliers
-
Oil industry sees war windfall but girds for political blowback
-
Anthropic's models gained unauthorized 'real-world' access during testing
-
Amazon beats expectations with cloud and AI growth
-
Apple tops estimates in CEO Cook's final quarter, but shares fall
-
Blowout Microsoft results lift US stocks as oil retreats
-
Milei demands expulsion of foreigners expressing 'hate' against Argentina
-
'Beginning of the end': Relief but no party as French wildfire winds down
-
Italy's Po River valley on drought alert
-
Southern Europe 'becoming more flammable' in hotter climate, experts say
-
Prada profits pinched as growth hard to chase
-
Mammoth bones found on parched bed of Danube in Bulgaria
-
Stocks climb on earnings and rates, oil retreats
-
MEXC Lists Grvt (GRVT) with $60,000 Worth of GRVT and 10,000 USDT in Airdrop+ Rewards
-
US economic growth slows in second quarter, missing expectations
-
George and Amal Clooney flee French home due to wildfire
-
Russia adds Telegram founder Durov to 'terrorist' blacklist
-
MEXC Ventures Supports Alpha Arena's APAC Debut at Coinfest Bali
-
Stocks diverge on earnings, as oil steadies
-
AI data centre supplier Zhongji InnoLight slips on Hong Kong debut
-
Eurozone economy grows despite Middle East war
-
May, June heatwaves caused 2,877 extra deaths in England: govt
-
Singapore group will develop 'most promising' Ebola vaccine
Novo Nordisk to slash prices of weightloss drugs in US
Danish drugmaker Novo Nordisk, which is struggling with competition for its anti-obesity treatments, said Tuesday that it will sharply cut prices for its flagship drugs in the US, announcing a 50 percent cut for Wegovy and 35 percent for Ozempic.
"This decision applies to all doses of these medicines and reflects Novo Nordisk's commitment to enhancing affordability for patients and both public and private payers dealing with the complexities of the evolving US healthcare system," the company said in a statement.
Effective January 1, 2027, the list price will be $675 for a month's worth of Wegovy, which currently costs around $1,350 a month.
Ozempic and Rybelsus, treatments that each currently come to about $1,000, will also be priced $675.
Novo Nordisk said the price reduction is meant to make it possible to reach more patients.
"Lowering the list price of Wegovy and Ozempic is the best approach to address the unprecedented opportunity to help more than 100 million people living with obesity and over 35 million people with type 2 diabetes in the United States," Jamey Millar, executive vice president of Novo Nordisk's US Operations, said.
In early February, Novo Nordisk vowed legal against US chain Hims & Hers for offering a copycat of the new pill version of Wegovy.
Limited production capacity for the blockbuster drug led the FDA to temporarily allow pharmacies to create so-called "compound" or copycat versions of Wegovy and Ozempic, an analogue used to treat diabetes.
That authorisation expired last May 22 but Novo Nordisk has complained of copycat versions of its drugs still being available.
Ozempic is an injectable anti-diabetic treatment that became popular on social media for its slimming properties.
Wegovy, which has the same active ingredient as Ozempic in a different dose, is a weight-loss drug and is also available in pill form.
Both treatments use analogues of the hormone GLP-1, which regulates blood glucose levels and appetite.
Shares in Novo Nordisk have taken a beating in recent weeks after it warned in early February of lower sales revenue in the United States as intensified competition pushes down prices.
They fell 3.8 percent in afternoon trading in Copenhagen.
H.Meyer--CPN